Hepcidin Therapeutics
Open accessThe DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
Hepcidin is a key hormonal regulator of systemic iron homeostasis and its expression is induced by iron or inflammatory stimuli. Genetic defects in iron signaling to hepcidin lead to “hepcidinopathies” ranging from hereditary hemochromatosis to iron-refractory iron deficiency anemia, which are disorders caused by hepcidin deficiency or excess, respectively. Moreover, dysregulation of hepcidin is a pathogenic cofactor in iron-loading anemias with ineffective erythropoiesis and in anemia of inflammation. Experiments with preclinical animal models provided evidence that restoration of appropriate hepcidin levels can be used for the treatment of these conditions. This fueled the rapidly growing field of hepcidin therapeutics. Several hepcidin agonists and antagonists, as well as inducers and inhibitors of hepcidin expression have been identified to date. Some of them were further developed and are currently being evaluated in clinical trials. This review summarizes the state of the art.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803 · cited 1×
“The binding of hepcidin occludes iron efflux [5] and triggers ubiquitination, internalization and lysosomal degradation of ferroportin [6].”
BackgroundNemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650 · cited 1×
“IL-6 is critical for inflammatory induction of hepcidin, and Il6-/- (IL-6 knockout) mice exhibit an impaired hypoferremic response to acute inflammation [122].”
BackgroundVitamin D metabolism, mechanism of action, and clinical applications
Bikle, D. D. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.12.016 · Cited by 1,933
Adverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
A Red carpet for iron metabolism
Muckenthaler, M. U., Rivella, S., Hentze, M. W., & Galy, B. (2017) · Cell · doi:10.1016/j.cell.2016.12.034 · Cited by 1,319 · cited 2×
“Efficient iron signaling to hepcidin requires auxiliary factors, such as BMP2, the BMP coreceptor hemojuvelin (HJV), the hemochromatosis protein HFE, and the diferric transferrin sensor transferrin receptor 2 (TfR2) [12].”
BackgroundIdentification of erythroferrone as an erythroid regulator of iron metabolism
Kautz, L., Jung, G., Valore, E. V., Rivella, S., Nemeth, E., & Ganz, T. (2014) · Nature Genetics · doi:10.1038/ng.2996 · Cited by 1,127 · cited 3×
“expression is suppressed by erythroferrone (ERFE), a hormone secreted by erythroblasts in response to erythropoietin [23] that neutralizes BMP6 [24].”
BackgroundGanz, T. (2013) · Physiological Reviews · doi:10.1152/physrev.00008.2013 · Cited by 1,122
Papanikolaou, G., & Pantopoulos, K. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.06.021 · Cited by 1,070 · cited 1×
“Accumulation of excess iron in cells is toxic, because “free” ferrous iron catalyzes the generation of hydroxyl radicals via Fenton chemistry, which attack and inactivate cellular macromolecules [1].”
BackgroundSelf-citationPathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease
Yoshizaki, K., Matsuda, T., Nishimoto, N., Kuritani, T., Taeho, L., Aozasa, K., Nakahata, T., Kawai, H., Tagoh, H., & Komori, T. (1989) · Blood · doi:10.1182/blood.v74.4.1360.1360 · Cited by 928 · cited 3×
“Castleman disease patients present with iron-refractory hypochromic microcytic anemia, which develops in response to IL-6-mediated upregulation of hepcidin [41].”
BackgroundIron homeostasis in host defence and inflammation
Ganz, T., & Nemeth, E. (2015) · Nature Reviews Immunology · doi:10.1038/nri3863 · Cited by 843 · cited 2×
“On the other hand, BMP6 and HJV are critical components of the inflammatory hepcidin pathway [19,20], which is considered as an innate immune response to depriv i v ding bacteria of iron [21].”
BackgroundChemistry and biology of eukaryotic iron metabolism
Aisen, P. (2001) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(01)00063-2 · Cited by 804
BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism
Andriopoulos Jr, B., Corradini, E., Xia, Y., Faasse, S. A., Chen, S., Grgurevic, L., Knutson, M. D., Pietrangelo, A., Vukicevic, S., Lin, H. Y., et al. (2009) · Nature Genetics · doi:10.1038/ng.335 · Cited by 769 · cited 13×
“There is increasing evidence for a cross-talk between JAK/STAT and BMP6/SMAD signaling during inflammato y hepcidin i duction [14–16].”
BackgroundInfluentialBrissot, P., Pietrangelo, A., Adams, P. C., de Graaff, B., McLaren, C. E., & Loréal, O. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.16 · Cited by 430
Torti, S. V., Manz, D. H., Paul, B. T., Blanchette-Farra, N., & Torti, F. M. (2018) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-082117-051732 · Cited by 426
Hunter, H. N., Fulton, D. B., Ganz, T., & Vogel, H. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205305200 · Cited by 400 · cited 5×
“It folds to a distorted β-sheet with an unusual disulfide bridge between adjacent C13-C14 at the turn of a hairpin loop; according to this model, the structure is stabilized by further disulfide bonding between C7-C23, C10-C22 and C11-C19 [7] (Figure 2, left).”
BackgroundInfluentialTargeting iron metabolism in drug discovery and delivery
Crielaard, B. J., Lammers, T., & Rivella, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.248 · Cited by 352
Suppression of iron-regulatory hepcidin by vitamin D
Bacchetta, J., Zaritsky, J. J., Sea, J. L., Chun, R. F., Lisse, T. S., Zavala, K., Nayak, A., Wesseling-Perry, K., Westerman, M., Hollis, B. W., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013040355 · Cited by 350
Aschemeyer, S., Qiao, B., Stefanova, D., Valore, E. V., Sek, A. C., Ruwe, T. A., Vieth, K. R., Jung, G., Casu, C., Rivella, S., et al. (2018) · Blood · doi:10.1182/blood-2017-05-786590 · Cited by 325 · cited 1×
“The binding of hepcidin occludes iron efflux [5] and triggers ubiquitination, internalization and lysosomal degradation of ferroportin [6].”
BackgroundConstitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis
Nicolas, G., Viatte, L., Lou, D.-Q., Bennoun, M., Beaumont, C., Kahn, A., Andrews, N. C., & Vaulont, S. (2003) · Nature Genetics · doi:10.1038/ng1150 · Cited by 311 · cited 1×
“Thus, iron overload was corrected when these animals were crossed with mice overexpressing transgenic hepcidin [54,55], or with Tmprss6-/- mice overexpressing endogenous hepcidin [56,57].”
BackgroundRivera, S., Nemeth, E., Gabayan, V., Lopez, M. A., Farshidi, D., & Ganz, T. (2005) · Blood · doi:10.1182/blood-2005-04-1766 · Cited by 308 · cited 1×
“Administration of synthetic hepcidin can effectively reduce plasma iron levels in wild type [81] or Hfe-/- mice [82].”
BackgroundErythroferrone inhibits the induction of hepcidin by BMP6
Arezes, J., Foy, N., McHugh, K., Sawant, A., Quinkert, D., Terraube, V., Brinth, A., Tam, M., LaVallie, E. R., Taylor, S., et al. (2018) · Blood · doi:10.1182/blood-2018-06-857995 · Cited by 277 · cited 3×
“expression is suppressed by erythroferrone (ERFE), a hormone secreted by erythroblasts in response to erythropoietin [23] that neutralizes BMP6 [24].”
BackgroundNemeth, E., Preza, G. C., Jung, C.-L., Kaplan, J., Waring, A. J., & Ganz, T. (2006) · Blood · doi:10.1182/blood-2005-05-2049 · Cited by 273 · cited 3×
“Mutational studies revealed that the N-terminus of hepcidin is necessary and sufficient for binding to ferroportin, and the remaining sequence is permissive to mutations [9].”
BackgroundMiura, K., Taura, K., Kodama, Y., Schnabl, B., & Brenner, D. A. (2008) · Hepatology · doi:10.1002/hep.22486 · Cited by 270 · cited 1×
“The hepcidin-stimulating effects of vorinostat in Huh7 hepatoma cells were also validated in another study [75], and are consistent with earlier data showing that the histone deacetylase inhibitor trichostatin A induces hepcidin by inhibiting the binding of C/EBPα and STAT3 in the HAMP promoter [76].”
Sasu, B. J., Cooke, K. S., Arvedson, T. L., Plewa, C., Ellison, A. R., Sheng, J., Winters, A., Juan, T., Li, H., Begley, C. G., et al. (2010) · Blood · doi:10.1182/blood-2009-09-245977 · Cited by 251
Bachman, E., Feng, R., Travison, T., Li, M., Olbina, G., Ostland, V., Ulloor, J., Zhang, A., Basaria, S., Ganz, T., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0864 · Cited by 247
Preza, G. C., Ruchala, P., Pinon, R., Ramos, E., Qiao, B., Peralta, M. A., Sharma, S., Waring, A., Ganz, T., & Nemeth, E. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57693 · Cited by 234 · cited 2×
“By contrast, ri-hep9 and palmitoyl-ri-hep9 promoted hypoferremia, while high doses of the latter had almost the same effect on serum iron levels to equivalent doses of full-length hepcidin [83].”
BackgroundSong, S.-N. J., Tomosugi, N., Kawabata, H., Ishikawa, T., Nishikawa, T., & Yoshizaki, K. (2010) · Blood · doi:10.1182/blood-2010-03-271791 · Cited by 228 · cited 1×
“In addition, tocilizumab [127], as well as the anti-IL-6 antibody siltuximab [128], lowered hepcidin and ameliorated anemia in multicentric Castleman disease patients.”
BackgroundArezes, J., Jung, G., Gabayan, V., Valore, E., Ruchala, P., Gulig, P. A., Ganz, T., Nemeth, E., & Bulut, Y. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2014.12.001 · Cited by 227 · cited 1×
“Treatment of Hamp-/- mice with PR73, pre- or 3 h post-infection with siderophilic Vibrio vulnificus, caused hypoferremia and eventually repressed bacterial growth and reduced mortality [88].”
BackgroundHepcidin: regulation of the master iron regulator
Rishi, G., Wallace, D. F., & Subramaniam, V. N. (2015) · Bioscience Reports · doi:10.1042/bsr20150014 · Cited by 223
Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice
Gardenghi, S., Ramos, P., Marongiu, M. F., Melchiori, L., Breda, L., Guy, E., Muirhead, K., Rao, N., Roy, C. N., Andrews, N. C., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41717 · Cited by 220 · cited 2×
“Moreover, the increased hepcidin expression by these manipulations led to improved erythropoiesis in Hbbth3/+ mice [55,57].”
BackgroundAssociation of hemochromatosis with infectious diseases: expanding spectrum
Khan, F. A., Fisher, M. A., & Khakoo, R. A. (2007) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2007.04.007 · Cited by 216
Hepcidin Revisited, Disulfide Connectivity, Dynamics, and Structure
Jordan, J. B., Poppe, L., Haniu, M., Arvedson, T., Syed, R., Li, V., Kohno, H., Kim, H., Schnier, P. D., Harvey, T. S., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.017764 · Cited by 214 · cited 2×
“alt r ti l postulates disulfide bond connectivity between 7-C23, C10-C13, 1-C19 and 14-C22 [8] (Figure 2, right).”
BackgroundMinihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis
Ramos, E., Ruchala, P., Goodnough, J. B., Kautz, L., Preza, G. C., Nemeth, E., & Ganz, T. (2012) · Blood · doi:10.1182/blood-2012-07-440743 · Cited by 213 · cited 1×
“The effects of PR65 in iron-loaded Hamp-/- mice were less compelling, and limited to partial iron re-distribution from the liver to the spleen [84].”
Background17β-Estradiol Inhibits Iron Hormone Hepcidin Through an Estrogen Responsive Element Half-Site
Yang, Q., Jian, J., Katz, S., Abramson, S. B., & Huang, X. (2012) · Endocrinology · doi:10.1210/en.2011-2045 · Cited by 208
Schmidt, P. J., Toudjarska, I., Sendamarai, A. K., Racie, T., Milstein, S., Bettencourt, B. R., Hettinger, J., Bumcrot, D., & Fleming, M. D. (2013) · Blood · doi:10.1182/blood-2012-09-453977 · Cited by 204
Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats
Theurl, I., Schroll, A., Sonnweber, T., Nairz, M., Theurl, M., Willenbacher, W., Eller, K., Wolf, D., Seifert, M., Sun, C. C., et al. (2011) · Blood · doi:10.1182/blood-2011-03-345066 · Cited by 189
Hepcidin regulation in prostate and its disruption in prostate cancer
Tesfay, L., Clausen, K. A., Kim, J. W., Hegde, P., Wang, X., Miller, L. D., Deng, Z., Blanchette, N., Arvedson, T., Miranti, C. K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2465 · Cited by 186
An essential cell-autonomous role for hepcidin in cardiac iron homeostasis
Lakhal-Littleton, S., Wolna, M., Chung, Y. J., Christian, H. C., Heather, L. C., Brescia, M., Ball, V., Diaz, R., Santos, A., Biggs, D., et al. (2016) · eLife · doi:10.7554/elife.19804 · Cited by 184 · cited 1×
“Hepcidin is produced at lower levels in several extrahepatic tissues, including the heart or the brain, where it exerts local cell autonomous functions [42,43].”
BackgroundBesson-Fournier, C., Latour, C., Kautz, L., Bertrand, J., Ganz, T., Roth, M.-P., & Coppin, H. (2012) · Blood · doi:10.1182/blood-2012-02-411470 · Cited by 179 · cited 2×
“Activin B, a JAK/STAT-induced ligand of BMP receptors can ctiv te SMAD signaling to hepcidin [17], but its function is not ess ntial [18].”
BackgroundDorsomorphin and LDN-193189 inhibit BMP-mediated Smad, p38 and Akt signalling in C2C12 cells
Boergermann, J. H., Kopf, J., Yu, P. B., & Knaus, P. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.07.018 · Cited by 175 · cited 1×
“A major limitation of LDN-193189 as hepcidin inhibitor is its broad specificity that leads to off-target effects [109,110].”
BackgroundThe role of vitamin D in regulating the iron-hepcidin-ferroportin axis in monocytes
Zughaier, S. M., Alvarez, J. A., Sloan, J. H., Konrad, R. J., & Tangpricha, V. (2014) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2014.01.003 · Cited by 174 · cited 2×
“Experiments in cultured hepatoma cells, monocytic cells and peripheral blood monocytes demonstrated that vitamin D inhibits expression of inflammatory cytokines; and suppresses hepcidin by a mechanism involving VDR binding to the HAMP promoter [161,162].”
BackgroundPietrangelo, A. (2016) · Liver International · doi:10.1111/liv.13020 · Cited by 174
Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation
Steinbicker, A. U., Sachidanandan, C., Vonner, A. J., Yusuf, R. Z., Deng, D. Y., Lai, C. S., Rauwerdink, K. M., Winn, J. C., Saez, B., Cook, C. M., et al. (2011) · Blood · doi:10.1182/blood-2010-10-313064 · Cited by 173
Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia
Nai, A., Pagani, A., Mandelli, G., Lidonnici, M. R., Silvestri, L., Ferrari, G., & Camaschella, C. (2012) · Blood · doi:10.1182/blood-2012-01-401885 · Cited by 161
Schwoebel, F., van Eijk, L. T., Zboralski, D., Sell, S., Buchner, K., Maasch, C., Purschke, W. G., Humphrey, M., Zöllner, S., Eulberg, D., et al. (2013) · Blood · doi:10.1182/blood-2012-09-456756 · Cited by 158
Ferroportin disease: pathogenesis, diagnosis and treatment
Pietrangelo, A. (2017) · Haematologica · doi:10.3324/haematol.2017.170720 · Cited by 151
Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera
Casu, C., Oikonomidou, P. R., Chen, H., Nandi, V., Ginzburg, Y., Prasad, P., Fleming, R. E., Shah, Y. M., Valore, E. V., Nemeth, E., et al. (2016) · Blood · doi:10.1182/blood-2015-10-676742 · Cited by 148 · cited 2×
“Interestingly, M009 was also shown to reduce erythrocytosis and splenomegaly in a mouse model of polycythemia vera [92].”
BackgroundHeparin: a potent inhibitor of hepcidin expression in vitro and in vivo
Poli, M., Girelli, D., Campostrini, N., Maccarinelli, F., Finazzi, D., Luscieti, S., Nai, A., & Arosio, P. (2011) · Blood · doi:10.1182/blood-2010-06-289082 · Cited by 148
Stefanova, D., Raychev, A., Arezes, J., Ruchala, P., Gabayan, V., Skurnik, M., Dillon, B. J., Horwitz, M. A., Ganz, T., Bulut, Y., et al. (2017) · Blood · doi:10.1182/blood-2017-03-772715 · Cited by 145 · cited 1×
“Similar results were obtained in Hamp-/- or iron-loaded wild type mice infected with siderophilic Yersinia enterocolitica [89], or non-siderophilic Klebsiella pneumoniae or Escherichia coli [90,91].”
ResultA mouse model of anemia of inflammation: complex pathogenesis with partial dependence on hepcidin
Kim, A., Fung, E., Parikh, S. G., Valore, E. V., Gabayan, V., Nemeth, E., & Ganz, T. (2014) · Blood · doi:10.1182/blood-2013-08-521419 · Cited by 145 · cited 1×
“Moreover, inoculation of Hamp-/- or IL6-/mice with heat-killed Brucella abortus yielded a milder AI phenotype [62,63].”
BackgroundPharmacological Targeting of the Hepcidin/Ferroportin Axis
Sebastiani, G., Wilkinson, N., & Pantopoulos, K. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00160 · Cited by 127
Self-citationLatour, C., Kautz, L., Besson-Fournier, C., Island, M.-L., Canonne-Hergaux, F., Loréal, O., Ganz, T., Coppin, H., & Roth, M.-P. (2014) · Hepatology · doi:10.1002/hep.26648 · Cited by 120 · cited 1×
“Testosterone, the primary male sex hormone and anabolic steroid, inhibits hepcidin by enhancing epidermal growth factor receptor (EGFR) signaling [146] and by reducing BMP/SMAD signaling [147].”
BackgroundNúñez, G., Sakamoto, K., & Soares, M. P. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800325 · Cited by 115 · cited 1×
“This is part of a broader iron withholding strategy within the context of “nutritional immunity” [22].”
BackgroundProgesterone receptor membrane component-1 regulates hepcidin biosynthesis
Li, X., Rhee, D. K., Malhotra, R., Mayeur, C., Hurst, L. A., Ager, E., Shelton, G., Kramer, Y., McCulloh, D., Keefe, D., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci83831 · Cited by 112 · cited 1×
“They operate via a pathway involving the progesterone receptor membrane component-1 (PRMC-1) [71].”
Backgroundvan Eijk, L. T., John, A. S. E., Schwoebel, F., Summo, L., Vauléon, S., Zöllner, S., Laarakkers, C. M., Kox, M., van der Hoeven, J. G., Swinkels, D. W., et al. (2014) · Blood · doi:10.1182/blood-2014-03-559484 · Cited by 110 · cited 1×
“In another phase 1 trial with human volunteers who developed endotoxemia following lipopolysaccharide injections, NOX-H94 neutralized high levels of hepcidin and corrected endotoxin-induced hypoferremia [177].”
BackgroundCorradini, E., Schmidt, P. J., Meynard, D., Garuti, C., Montosi, G., Chen, S., Vukicevic, S., Pietrangelo, A., Lin, H. Y., & Babitt, J. L. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.07.044 · Cited by 109 · cited 1×
“Treatment of Hfe-/- mice with the major hepcidin inducer BMP6 was shown to increase hepatic hepcidin expression, which in turn caused a decrease in serum iron levels, due to iron retention in the spleen and the duodenum [64].”
BackgroundGardenghi, S., Renaud, T. M., Meloni, A., Casu, C., Crielaard, B. J., Bystrom, L. M., Greenberg-Kushnir, N., Sasu, B. J., Cooke, K. S., & Rivella, S. (2014) · Blood · doi:10.1182/blood-2013-08-521625 · Cited by 107 · cited 1×
“Moreover, inoculation of Hamp-/- or IL6-/mice with heat-killed Brucella abortus yielded a milder AI phenotype [62,63].”
BackgroundIsaacs, J. D., Harari, O., Kobold, U., Lee, J. S., & Bernasconi, C. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4397 · Cited by 105
Casper, C., Chaturvedi, S., Munshi, N., Wong, R., Qi, M., Schaffer, M., Bandekar, R., Hall, B., van de Velde, H., Vermeulen, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0134 · Cited by 97 · cited 1×
“In addition, tocilizumab [127], as well as the anti-IL-6 antibody siltuximab [128], lowered hepcidin and ameliorated anemia in multicentric Castleman disease patients.”
BackgroundHepcidin-mediated iron sequestration protects against bacterial dissemination during pneumonia
Michels, K. R., Zhang, Z., Bettina, A. M., Cagnina, R. E., Stefanova, D., Burdick, M. D., Vaulont, S., Nemeth, E., Ganz, T., & Mehrad, B. (2017) · JCI Insight · doi:10.1172/jci.insight.92002 · Cited by 93 · cited 1×
“Similar results were obtained in Hamp-/- or iron-loaded wild type mice infected with siderophilic Yersinia enterocolitica [89], or non-siderophilic Klebsiella pneumoniae or Escherichia coli [90,91].”
ResultTmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice
Finberg, K. E., Whittlesey, R. L., & Andrews, N. C. (2011) · Blood · doi:10.1182/blood-2010-10-315507 · Cited by 81 · cited 1×
“Thus, iron overload was corrected when these animals were crossed with mice overexpressing transgenic hepcidin [54,55], or with Tmprss6-/- mice overexpressing endogenous hepcidin [56,57].”
BackgroundHigh-throughput screening of small molecules identifies hepcidin antagonists
Fung, E., Sugianto, P., Hsu, J., Damoiseaux, R., Ganz, T., & Nemeth, E. (2013) · Molecular Pharmacology · doi:10.1124/mol.112.083428 · Cited by 78
Schmidt, P. J., Racie, T., Westerman, M., Fitzgerald, K., Butler, J. S., & Fleming, M. D. (2015) · American Journal of Hematology · doi:10.1002/ajh.23934 · Cited by 77 · cited 1×
“Hbbth3/+ mice with Tmprss6 siRNAs or ASOs, together with the oral iron chelator deferiprone, resulted in better correction of erythropoiesis and prevention of secondary iron overload [67,68].”
BackgroundThe small molecule, genistein, increases hepcidin expression in human hepatocytes
Zhen, A. W., Nguyen, N. H., Gibert, Y., Motola, S., Buckett, P., Wessling-Resnick, M., Fraenkel, E., & Fraenkel, P. G. (2013) · Hepatology · doi:10.1002/hep.26490 · Cited by 74 · cited 1×
“Genistein was shown to upregulate hepcidin in HepG2 hepatoma cells and zebrafish embryos by promoting STAT3 phosphorylation [72].”
BackgroundMleczko-Sanecka, K., Roche, F., Rita da Silva, A., Call, D., D’Alessio, F., Ragab, A., Lapinski, P. E., Ummanni, R., Korf, U., Oakes, C., et al. (2014) · Blood · doi:10.1182/blood-2013-07-515957 · Cited by 74 · cited 2×
“On the other hand, activation of AMPK by metformin was reported to induce hepcidin in cultured Huh7 hepatoma cells [79]; these seemingly conflicting data highlight the need for more mechanistic studies.”
BackgroundHashizume, M., Uchiyama, Y., Horai, N., Tomosugi, N., & Mihara, M. (2010) · Rheumatology International · doi:10.1007/s00296-009-1075-4 · Cited by 70
Stefanova, D., Raychev, A., Deville, J., Humphries, R., Campeau, S., Ruchala, P., Nemeth, E., Ganz, T., & Bulut, Y. (2018) · Infection and Immunity · doi:10.1128/iai.00253-18 · Cited by 68
Investigation of a Researcher's Death Due to Septicemic Plague
Frank, K. M., Schneewind, O., & Shieh, W.-J. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1010939 · Cited by 62 · cited 1×
“In addition, HH patients are susceptible to infection with siderophilic bacteria, but also various other pathogens [26,27].”
BackgroundFatih, N., Camberlein, E., Island, M. L., Corlu, A., Abgueguen, E., Détivaud, L., Leroyer, P., Brissot, P., & Loréal, O. (2010) · Journal of Molecular Medicine · doi:10.1007/s00109-009-0588-3 · Cited by 59
Iron-deficiency anemia in Castleman disease: implication of the interleukin 6/hepcidin pathway
Arlet, J.-B., Hermine, O., Darnige, L., Ostland, V., Westerman, M., Badoual, C., Pouchot, J., & Capron, L. (2010) · PEDIATRICS · doi:10.1542/peds.2010-1123 · Cited by 46 · cited 1×
“Castleman disease patients present with iron-refractory hypochromic microcytic anemia, which develops in response to IL-6-mediated upregulation of hepcidin [41].”
BackgroundTheurl, M., Nairz, M., Schroll, A., Sonnweber, T., Asshoff, M., Haschka, D., Seifert, M., Willenbacher, W., Wilflingseder, D., Posch, W., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.099481 · Cited by 42
Mayeur, C., Kolodziej, S. A., Wang, A., Xu, X., Lee, A., Yu, P. B., Shen, J., Bloch, K. D., & Bloch, D. B. (2015) · Haematologica · doi:10.3324/haematol.2014.111484 · Cited by 38 · cited 1×
“Orally administered LDN-193189 was also shown to increase hemoglobinization in turpentine-challenged mice [107].”
BackgroundAG490: An inhibitor of hepcidin expression in vivo
Zhang, S.-P. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i45.5032 · Cited by 35
Böser, P., Seemann, D., Liguori, M. J., Fan, L., Huang, L., Hafner, M., Popp, A., & Mueller, B. K. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9770-4 · Cited by 35 · cited 1×
“A single-dose of the HJV-neutralizing antibodies ABT-207 or H5F9-AM8 in rats and cynomolgus monkeys had long-lasting suppressing effects on hepcidin and promoted an increase in serum iron [103].”
BackgroundIdentification of Antibody and Small Molecule Antagonists of Ferroportin-Hepcidin Interaction
Ross, S. L., Biswas, K., Rottman, J., Allen, J. R., Long, J., Miranda, L. P., Winters, A., & Arvedson, T. L. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00838 · Cited by 33
Witcher, D. R., Leung, D., Hill, K. A., De Rosa, D. C., Xu, J., Manetta, J., Wroblewski, V. J., & Benschop, R. J. (2013) · Blood · doi:10.1182/blood.v122.21.3433.3433 · Cited by 29
A chemical screen identifies small molecules that regulate hepcidin expression
Gaun, V., Patchen, B., Volovetz, J., Zhen, A. W., Andreev, A., Pollastri, M. P., & Fraenkel, P. G. (2014) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2014.06.002 · Cited by 22 · cited 1×
“They both stimulate expression of hepcidin and other BMP- and STAT3-dependent genes without affecting SMAD1/5/8 or STAT3 phosphorylation, and exhibit 10-fold higher potency than genistein [73].”
BackgroundMoebius, U., Feuerer, W., Fenzl, E., van Swelm, R., Swinkels, D. W., & Hohlbaum, A. (2015) · Blood · doi:10.1182/blood.v126.23.536.536 · Cited by 14
Peterson, P., Soh, K. K., Lee, Y. S., Kim, W., Whatcott, C. J., Siddiqui-Jain, A., Bearss, D. J., & Warner, S. L. (2015) · Blood · doi:10.1182/blood.v126.23.273.273 · Cited by 10 · cited 1×
“In preclinical mouse models of inflammation- and cancer-induced anemia, TP-0184 decreased hepatic hepcidin mRNA and improved hemoglobinization [117,118].”
Background
Research works printed but not linked: 103
- Papanikolaou, 2017, Systemic iron homeostasis and erythropoiesis, IUBMB Life, 69, 399, 10.1002/iub.1629 · DOI
- Pandur, 2018, The C19S Substitution Enhances the Stability of Hepcidin While Conserving Its Biological Activity, Protein J., 37, 113, 10.1007/s10930-018-9759-9 · DOI
- Wahedi, 2017, Matriptase-2 suppresses hepcidin expression by cleaving multiple components of the hepcidin induction pathway, J. Biol. Chem., 292, 18354, 10.1074/jbc.M117.801795 · DOI
- Mayeur, 2014, The type I BMP receptor Alk3 is required for the induction of hepatic hepcidin gene expression by interleukin-6, Blood, 123, 2261, 10.1182/blood-2013-02-480095 · DOI · Paper page
- Gineste, 2017, Hepcidin upregulation by inflammation is independent of Smad1/5/8 signaling by activin B, Blood, 129, 533, 10.1182/blood-2016-10-748541 · DOI
- Latour, 2017, Deletion of BMP6 worsens the phenotype of HJV-deficient mice and attenuates hepcidin levels reached after LPS challenge, Blood, 130, 2339, 10.1182/blood-2017-07-795658 · DOI · Paper page
- Fillebeen, 2018, Hepcidin-mediated hypoferremic response to acute inflammation requires a threshold of Bmp6/Hjv/Smad signaling, Blood, 132, 1829, 10.1182/blood-2018-03-841197 · DOI
- Pantopoulos, 2018, Inherited Disorders of Iron Overload, Front. Nutr., 5, 103, 10.3389/fnut.2018.00103 · DOI
- Gupta, 2018, Ineffective Erythropoiesis: Anemia and Iron Overload, Hematol. Oncol. Clin. N. Am., 32, 213, 10.1016/j.hoc.2017.11.009 · DOI · Paper page
- Kowdley, 2016, Iron Overload in Patients with Chronic Liver Disease, Gastroenterol. Hepatol. (N. Y.), 12, 695
- Vela, 2018, Low hepcidin in liver fibrosis and cirrhosis; a tale of progressive disorder and a case for a new biochemical marker, Mol. Med., 24, 5, 10.1186/s10020-018-0008-7 · DOI
- Han, 2016, Hepcidin inhibits Smad3 phosphorylation in hepatic stellate cells by impeding ferroportin-mediated regulation of Akt, Nat. Commun., 7, 13817, 10.1038/ncomms13817 · DOI
- Folgueras, 2018, Matriptase-2 deficiency protects from obesity by modulating iron homeostasis, Nat. Commun., 9, 1350, 10.1038/s41467-018-03853-1 · DOI · Paper page
- Heeney, 2014, Iron-Refractory Iron Deficiency Anemia (IRIDA), Hematol. Oncol. Clin. N. Am., 28, 637, 10.1016/j.hoc.2014.04.009 · DOI
- Fraenkel, 2017, Anemia of Inflammation: A Review, Med. Clin. N. Am., 101, 285, 10.1016/j.mcna.2016.09.005 · DOI · Paper page
- Ueda, 2017, Role of Hepcidin-25 in Chronic Kidney Disease: Anemia and Beyond, Curr. Med. Chem., 24, 1417, 10.2174/0929867324666170316120538 · doi:10.2174/0929867324666170316120538
- Nairz, 2016, Iron deficiency or anemia of inflammation?: Differential diagnosis and mechanisms of anemia of inflammation, Wien. Med. Wochenschr., 166, 411, 10.1007/s10354-016-0505-7 · DOI · Paper page
- You, 2017, Astrocyte hepcidin is a key factor in LPS-induced neuronal apoptosis, Cell Death Dis., 8, e2676, 10.1038/cddis.2017.93 · DOI · Paper page
- Pinnix, 2010, Ferroportin and iron regulation in breast cancer progression and prognosis, Sci. Transl. Med., 2, 43ra56, 10.1126/scitranslmed.3001127 · DOI · Paper page
- Zhou, 2018, E4BP4 promotes thyroid cancer proliferation by modulating iron homeostasis through repression of hepcidin, Cell Death Dis., 9, 987, 10.1038/s41419-018-1001-3 · DOI
- Casu, 2018, Hepcidin agonists as therapeutic tools, Blood, 131, 1790, 10.1182/blood-2017-11-737411 · DOI · Paper page
- Sivakumar, 2016, Management of human factors engineering-associated hemochromatosis: A 2015 update, World J. Hepatol., 8, 395, 10.4254/wjh.v8.i8.395 · DOI
- Niederau, 1985, Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis, N. Engl. J. Med., 313, 1256, 10.1056/NEJM198511143132004 · DOI · Paper page
- Musallam, 2013, Cross-talk between available guidelines for the management of patients with beta-thalassemia major, Acta Haematol., 130, 64, 10.1159/000345734 · DOI
- Besarab, 2010, Iron supplementation to treat anemia in patients with chronic kidney disease, Nat. Rev. Nephrol., 6, 699, 10.1038/nrneph.2010.139 · DOI
- Biggar, 2017, Treatment of renal anemia: Erythropoiesis stimulating agents and beyond, Kidney Res. Clin. Pract., 36, 209, 10.23876/j.krcp.2017.36.3.209 · DOI
- Tzounakas, 2017, Red blood cell transfusion in surgical cancer patients: Targets, risks, mechanistic understanding and further therapeutic opportunities, Transfus. Apheresis Sci., 56, 291, 10.1016/j.transci.2017.05.015 · DOI
- Guo, 2013, Reducing TMPRSS6 ameliorates hemochromatosis and beta-thalassemia in mice, J. Clin. Investig., 123, 1531, 10.1172/JCI66969 · DOI · Paper page
- Casu, 2016, Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia, Haematologica, 101, e8, 10.3324/haematol.2015.133348 · DOI · Paper page
- Aghajan, 2016, Developing a Galnac-Conjugated TMPRSS6 Antisense Therapy for the Treatment of β-Thalassemia, Blood, 128, 1013, 10.1182/blood.V128.22.1013.1013 · doi:10.1182/blood.v128.22.1013.1013
- Schmidt, 2018, RNAi-mediated reduction of hepatic Tmprss6 diminishes anemia and secondary iron overload in a splenectomized mouse model of beta-thalassemia intermedia, Am. J. Hematol., 93, 745, 10.1002/ajh.25079 · DOI
- Patchen, 2016, Dietary supplementation with ipriflavone decreases hepatic iron stores in wild type mice, Blood Cells Mol. Dis., 60, 36, 10.1016/j.bcmd.2016.05.004 · DOI
- Call, 2017, Imatinib and spironolactone suppress hepcidin expression, Haematologica, 102, 1173, 10.3324/haematol.2016.162917 · DOI
- Zhang, 2016, Icariin regulates systemic iron metabolism by increasing hepatic hepcidin expression through Stat3 and Smad1/5/8 signaling, Int. J. Mol. Med., 37, 1379, 10.3892/ijmm.2016.2545 · DOI
- Bayele, 2015, Phytoestrogens modulate hepcidin expression by Nrf2: Implications for dietary control of iron absorption, Free Radic. Biol. Med., 89, 1192, 10.1016/j.freeradbiomed.2015.11.001 · DOI
- Zhang, 2018, Adenine alleviates iron overload by cAMP/PKA mediated hepatic hepcidin in mice, J. Cell. Physiol., 233, 7268, 10.1002/jcp.26559 · DOI
- Mendez, 2010, Hepcidin treatment in Hfe−/− mice diminishes plasma iron without affecting erythropoiesis, Eur. J. Clin. Investig., 40, 511, 10.1111/j.1365-2362.2010.02291.x · DOI · Paper page
- Fung, 2015, Thiol-derivatized minihepcidins retain biological activity, Bioorg. Med. Chem. Lett., 25, 763, 10.1016/j.bmcl.2014.12.094 · DOI
- Lunova, 2017, Hepcidin knockout mice spontaneously develop chronic pancreatitis owing to cytoplasmic iron overload in acinar cells, J. Pathol., 241, 104, 10.1002/path.4822 · DOI
- Chua, 2015, Small cyclic agonists of iron regulatory hormone hepcidin, Bioorg. Med. Chem. Lett., 25, 4961, 10.1016/j.bmcl.2015.03.012 · DOI
- Lal, A., Piga, A., Viprakasit, V., Maynard, J., Kattamis, A., Yaeger, D., Byrnes, B., Chawla, L., and Tidmarsh, G. (2018, January 14–17). A phase 1, open-label study to determine the safety, tolerability, and pharmacokinetics of escalating doses of LJPC-401 (synthetic human hepcidin) in patients with iron overload. Proceedings of the 23rd European Hematology Association Congress, Stockholm, Sweden. Abstract #S894.
- Bourne, G., Zhao, L., Bhandari, A., Frederick, B., McMahon, J., Tran, V., Annamalai, T., Mattheakis, L., Patel, D., and Smythe, M. (2018, January 14–17). Hepcidin Mimetic PTG-300 for Treatment of Ineffective Erythropoiesis and Chronic Anemia in Hemoglobinopathy Disease. Proceedings of the 23rd European Hematology Association Congress, Stockholm, Sweden. Abstract #S843.
- Nicholls, A., Lickliter, J., Tozzi, L., Liu, D., and Shames, R. (2018, January 14–17). Hepcidin mimetic PTG-300 induces dose-related and sustained reductions in serum iron and transferrin saturation in healthy subjects. Proceedings of the 23rd European Hematology Association Congress, Stockholm, Sweden. Abstract #S895.
- Abreu, 2018, Heparin inhibits intracellular Mycobacterium tuberculosis bacterial replication by reducing iron levels in human macrophages, Sci. Rep., 8, 7296, 10.1038/s41598-018-25480-y · DOI
- Poli, 2014, Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo, Blood, 123, 1564, 10.1182/blood-2013-07-515221 · DOI · Paper page
- Poli, 2014, Oversulfated heparins with low anticoagulant activity are strong and fast inhibitors of hepcidin expression in vitro and in vivo, Biochem. Pharmacol., 92, 467, 10.1016/j.bcp.2014.09.007 · DOI
- Seldin, 2014, Metabolic function of the CTRP family of hormones, Rev. Endocr. Metab. Disord., 15, 111, 10.1007/s11154-013-9255-7 · DOI · Paper page
- Babitt, 2007, Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance, J. Clin. Investig., 117, 1933, 10.1172/JCI31342 · DOI · Paper page
- Kovac, 2016, Anti-hemojuvelin antibody corrects anemia caused by inappropriately high hepcidin levels, Haematologica, 101, e173, 10.3324/haematol.2015.140772 · DOI · Paper page
- Yu, 2008, Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism, Nat. Chem. Biol., 4, 33, 10.1038/nchembio.2007.54 · DOI · Paper page
- Kanamori, 2016, Regulation of hepcidin expression by inflammation-induced activin B, Sci. Rep., 6, 38702, 10.1038/srep38702 · DOI
- Vogt, 2011, The specificities of small molecule inhibitors of the TGFss and BMP pathways, Cell. Signal., 23, 1831, 10.1016/j.cellsig.2011.06.019 · DOI · Paper page
- Mohedas, 2013, Development of an ALK2-biased BMP type I receptor kinase inhibitor, ACS Chem. Biol., 8, 1291, 10.1021/cb300655w · DOI · Paper page
- Mu, 2016, The dietary flavonoid myricetin regulates iron homeostasis by suppressing hepcidin expression, J. Nutr. Biochem., 30, 53, 10.1016/j.jnutbio.2015.10.015 · DOI
- Fukuda, 2017, Synthesis and SAR studies of 3,6-disubstituted indazole derivatives as potent hepcidin production inhibitors, Bioorg. Med. Chem. Lett., 27, 2148, 10.1016/j.bmcl.2017.03.056 · DOI
- Fukuda, 2017, Discovery of DS28120313 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4,6-disubstituted indazole derivatives, Bioorg. Med. Chem. Lett., 27, 5252, 10.1016/j.bmcl.2017.10.031 · DOI
- Fukuda, 2017, Discovery of DS79182026: A potent orally active hepcidin production inhibitor, Bioorg. Med. Chem. Lett., 27, 3716, 10.1016/j.bmcl.2017.07.004 · DOI
- Sasaki, 2018, Target identification of hepcidin production inhibitors by a combination of chemical proteomics and radioactive compound binding assay, Biochem. Biophys. Res. Commun., 503, 2878, 10.1016/j.bbrc.2018.08.061 · DOI
- Peterson, 2016, The ALK-2 Inhibitor, TP-0184, Demonstrates High Distribution to the Liver Contributing to Significant Preclinical Efficacy in Mouse Models of Anemia of Chronic Disease (Abstract), Blood, 128, 263, 10.1182/blood.V128.22.263.263 · DOI
- Pardanani, 2013, Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis, Leukemia, 27, 1322, 10.1038/leu.2013.71 · DOI · Paper page
- Kuhrt, 2015, Emerging EPO and EPO receptor regulators and signal transducers, Blood, 125, 3536, 10.1182/blood-2014-11-575357 · DOI · Paper page
- Asshoff, 2017, Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents, Blood, 129, 1823, 10.1182/blood-2016-09-740092 · DOI · Paper page
- Jones, 2010, Tocilizumab: A review of its safety and efficacy in rheumatoid arthritis, Clin. Med. Insights Arthritis Musculoskelet. Disord., 3, 81, 10.4137/CMAMD.S4864 · DOI
- Song, 2013, Comparative evaluation of the effects of treatment with tocilizumab and TNF-alpha inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients, Arthritis Res. Ther., 15, R141, 10.1186/ar4323 · DOI · Paper page
- Suzuki, 2017, Hepcidin-25 gives an indication of the therapeutic effectiveness of tocilizumab in rheumatoid arthritis—Relationship between disease activity of rheumatoid arthritis and anemia, Rev. Bras. Reumatol. Engl. Ed., 57, 637, 10.1016/j.rbr.2016.07.004 · DOI
- Noguchi-Sasaki, M., Sasaki, Y., Shimonaka, Y., Mori, K., and Fujimoto-Ouchi, K. (2016). Treatment with anti-IL-6 receptor antibody prevented increase in serum hepcidin levels and improved anemia in mice inoculated with IL-6-producing lung carcinoma cells. BMC Cancer, 16. · DOI
- Laine, 2017, Curcuma decreases serum hepcidin levels in healthy volunteers: A placebo-controlled, randomized, double-blind, cross-over study, Fundam. Clin. Pharmacol., 31, 567, 10.1111/fcp.12288 · DOI
- Li, W.Y., Li, F.M., Zhou, Y.F., Wen, Z.M., Ma, J., Ya, K., and Qian, Z.M. (2016). Aspirin down Regulates Hepcidin by Inhibiting NF-kappaB and IL6/JAK2/STAT3 Pathways in BV-2 Microglial Cells Treated with Lipopolysaccharide. Int. J. Mol. Sci., 17. · DOI
- Huang, 2018, Aspirin increases ferroportin 1 expression by inhibiting hepcidin via the JAK/STAT3 pathway in interleukin 6-treated PC-12 cells, Neurosci. Lett., 662, 1, 10.1016/j.neulet.2017.10.001 · DOI
- Marcon, 2013, Maresin 1, a proresolving lipid mediator derived from omega-3 polyunsaturated fatty acids, exerts protective actions in murine models of colitis, J. Immunol., 191, 4288, 10.4049/jimmunol.1202743 · DOI · Paper page
- Wang, 2016, Maresin 1 ameliorates iron-deficient anemia in IL-10(−/−) mice with spontaneous colitis by the inhibition of hepcidin expression though the IL-6/STAT3 pathway, Am. J. Transl. Res., 8, 2758
- Liu, 2012, Polysaccharide isolated from Angelica sinensis inhibits hepcidin expression in rats with iron deficiency anemia, J. Med. Food, 15, 923, 10.1089/jmf.2012.2231 · DOI
- Wang, 2017, Acidic Polysaccharide from Angelica sinensis Reverses Anemia of Chronic Disease Involving the Suppression of Inflammatory Hepcidin and NF-kappaB Activation, Oxid. Med. Cell. Longev., 2017, 7601592, 10.1155/2017/7601592 · DOI
- Wang, 2018, Correction of Anemia in Chronic Kidney Disease with Angelica sinensis Polysaccharide via Restoring EPO Production and Improving Iron Availability, Front. Pharmacol., 9, 803, 10.3389/fphar.2018.00803 · DOI
- Olas, 2015, Hydrogen sulfide in signaling pathways, Clin. Chim. Acta, 439, 212, 10.1016/j.cca.2014.10.037 · DOI · Paper page
- Xin, 2016, Hydrogen Sulfide Attenuates Inflammatory Hepcidin by Reducing IL-6 Secretion and Promoting SIRT1-Mediated STAT3 Deacetylation, Antioxid. Redox Signal., 24, 70, 10.1089/ars.2015.6315 · DOI
- Wang, M., Tang, W., Xin, H., and Zhu, Y.Z. (2016). S-Propargyl-Cysteine, a Novel Hydrogen Sulfide Donor, Inhibits Inflammatory Hepcidin and Relieves Anemia of Inflammation by Inhibiting IL-6/STAT3 Pathway. PLoS ONE, 11. · DOI
- Wang, 2017, AMPK Serves as a Therapeutic Target Against Anemia of Inflammation, Antioxid. Redox Signal., 27, 251, 10.1089/ars.2016.6846 · DOI
- Angmo, 2017, Identification of Guanosine 5′-diphosphate as Potential Iron Mobilizer: Preventing the Hepcidin-Ferroportin Interaction and Modulating the Interleukin-6/Stat-3 Pathway, Sci. Rep., 7, 40097, 10.1038/srep40097 · DOI
- Guo, 2013, Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells, Aging Cell, 12, 280, 10.1111/acel.12052 · DOI · Paper page
- Ohlander, 2018, Erythrocytosis Following Testosterone Therapy, Sex. Med. Rev., 6, 77, 10.1016/j.sxmr.2017.04.001 · DOI · Paper page
- Guo, 2016, Effects of Testosterone on Erythropoiesis in a Female Mouse Model of Anemia of Inflammation, Endocrinology, 157, 2937, 10.1210/en.2016-1150 · DOI
- Bachman, 2014, Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: Evidence for a new erythropoietin/hemoglobin set point, J. Gerontol. A Biol. Sci. Med. Sci., 69, 725, 10.1093/gerona/glt154 · DOI · Paper page
- Beggs, 2014, Testosterone alters iron metabolism and stimulates red blood cell production independently of dihydrotestosterone, Am. J. Physiol. Endocrinol. Metab., 307, E456, 10.1152/ajpendo.00184.2014 · DOI
- Dhindsa, 2016, Effect of testosterone on hepcidin, ferroportin, ferritin and iron binding capacity in patients with hypogonadotropic hypogonadism and type 2 diabetes, Clin. Endocrinol. (Oxf.), 85, 772, 10.1111/cen.13130 · DOI
- Gagliano-Juca, T., Pencina, K.M., Ganz, T., Travison, T.G., Kantoff, P.W., Nguyen, P.L., Taplin, M.E., Kibel, A.S., Li, Z., and Huang, G. (2018). Mechanisms Responsible for Reduced Erythropoiesis during Androgen Deprivation Therapy in Men with Prostate Cancer. Am. J. Physiol. Endocrinol. Metab. · DOI
- Lehtihet, M., Bonde, Y., Beckman, L., Berinder, K., Hoybye, C., Rudling, M., Sloan, J.H., Konrad, R.J., and Angelin, B. (2016). Circulating Hepcidin-25 Is Reduced by Endogenous Estrogen in Humans. PLoS ONE, 11. · DOI · Paper page
- Bajbouj, 2018, Elevated Levels of Estrogen Suppress Hepcidin Synthesis and Enhance Serum Iron Availability in Premenopausal Women, Exp. Clin. Endocrinol. Diabetes, 126, 453, 10.1055/s-0043-124077 · DOI
- Smith, 2015, Vitamin D and anemia: Insights into an emerging association, Curr. Opin. Endocrinol. Diabetes Obes., 22, 432, 10.1097/MED.0000000000000199 · DOI · Paper page
- Smith, 2017, High-dose vitamin D3 reduces circulating hepcidin concentrations: A pilot, randomized, double-blind, placebo-controlled trial in healthy adults, Clin. Nutr., 36, 980, 10.1016/j.clnu.2016.06.015 · DOI · Paper page
- Smith, 2018, High-Dose Vitamin D3 Administration Is Associated with Increases in Hemoglobin Concentrations in Mechanically Ventilated Critically Ill Adults: A Pilot Double-Blind, Randomized, Placebo-Controlled Trial, JPEN J. Parenter. Enter. Nutr., 42, 87, 10.1177/0148607116678197 · DOI
- Atkinson, 2017, Pilot study of the effect of cholecalciferol supplementation on hepcidin in children with chronic kidney disease: Results of the D-fense Trial, Pediatr. Nephrol., 32, 859, 10.1007/s00467-016-3563-6 · DOI
- Panwar, B., McCann, D., Olbina, G., Westerman, M., and Gutierrez, O.M. (2018). Effect of calcitriol on serum hepcidin in individuals with chronic kidney disease: A randomized controlled trial. BMC Nephrol., 19. · DOI
- Cooke, 2013, A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates, Blood, 122, 3054, 10.1182/blood-2013-06-505792 · DOI · Paper page
- Krzyzanski, 2016, Pharmacodynamic Model of Hepcidin Regulation of Iron Homeostasis in Cynomolgus Monkeys, AAPS J., 18, 713, 10.1208/s12248-016-9886-1 · DOI
- Abonour, 2017, A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia, J. Hematol. Oncol., 10, 73, 10.1186/s13045-017-0427-x · DOI · Paper page
- Rothe, 2018, Anticalin((R)) Proteins as Therapeutic Agents in Human Diseases, BioDrugs, 32, 233, 10.1007/s40259-018-0278-1 · DOI
- Veronese, 2008, The impact of PEGylation on biological therapies, BioDrugs, 22, 315, 10.2165/00063030-200822050-00004 · DOI · Paper page
- Vater, 2015, Turning mirror-image oligonucleotides into drugs: The evolution of Spiegelmer((R)) therapeutics, Drug Discov. Today, 20, 147, 10.1016/j.drudis.2014.09.004 · DOI · Paper page
- Boyce, 2016, Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects, Br. J. Pharmacol., 173, 1580, 10.1111/bph.13433 · DOI · Paper page
- Macdougall, I.C., Rumjon, A., Cinco, J., Goldstein, L., Summo, L., Vauleon, S., and Riecke, K. (2015). Pharmacokinetics and pharmacodynamics of lexaptepid, a novel anti-hepcidin molecule, in ESA-resistant haemodialysis patients. Nephrol. Dial. Transplant., 20. · doi:10.1093/ndt/gfv182.08
- Georgiev, P., Lazaroiu, M., Ocroteala, L., Grudeva-Popova, J., Gheorghita, E., Vasilica, M., Popescu, S.M., Cucuianu, A., Summo, L., and Schwoebel, F. (2014). The anti-hepcidin Spiegelmer® Lexaptepid Pegol (NOX-H94) as treatment of anemia of chronic disease in patients with multiple myeloma, low grade lymphoma, and CLL: A phase II pilot study. Cancer Res., 74. · DOI
- Barrington, 2016, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Anti-Ferroportin Antibody in Patients with Anemia Due to Chronic Renal Failure (Abstract), Blood, 128, 1280, 10.1182/blood.V128.22.1280.1280 · DOI
Cited by
Iron Homeostasis and Ferroptosis in Human Diseases: Mechanisms and Therapeutic Prospects
Ru, Q., Li, Y., Chen, L., Wu, Y., Min, J., & Wang, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01969-z · Cited by 724
Targeting ferroptosis opens new avenues for the development of novel therapeutics
Sun, S., Shen, J., Jiang, J., Wang, F., & Min, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01606-1 · Cited by 608
Hepcidin and Iron in Health and Disease
Nemeth, E., & Ganz, T. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-032816 · Cited by 457
Charlebois, E., Fillebeen, C., Katsarou, A., Rabinovich, A., Wisniewski, K., Venkataramani, V., Michalke, B., Velentza, A., & Pantopoulos, K. (2022) · eLife · doi:10.7554/elife.81332 · Cited by 22
Self-citation
Metadata
- Authors
- Katsarou, A., & Pantopoulos, K.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2018-11-21
- Volume
- 11
- Issue
- 4
- Pages
- 127
- ISSN
- 1424-8247 (ISSN-L)
- OpenAlex
- W4229492953
- Cited by
- 112
- References
- 79
- FWCI
- 6.23
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Canadian Institutes of Health Research (PJT-159730)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.